Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Phenyltoloxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 0.69 |
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.53 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.53 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 0.70 |
| ▸ | DRD1 | P21728 | 2/20 | 0.70 |
| ▸ | DRD4 | P21917 | 1/20 | 0.70 |
| ▸ | DRD5 | P21918 | 1/20 | 0.70 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GMNN | O75496 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenyltoloxamine SCHEMBL10987348 | 0.88 | KDM4E (0.78) | KDM4ELMNADRD2DRD1DRD4 | |
| Phenyltoloxamine SCHEMBL29440538 | 0.88 | LMNA (0.77) | KDM4ELMNADRD2DRD1DRD4 | |
| Phenyltoloxamine SCHEMBL28854 | 0.83 | DRD1 (1.00) | KDM4ELMNADRD2DRD1DRD4 | |
| Phenyltoloxamine SCHEMBL5145512 | 0.83 | DRD1 (1.00) | KDM4ELMNADRD2DRD1DRD4 | |
| Citric Acid SCHEMBL8657218 | 0.82 | KDM4E (0.70) | KDM4ELMNADRD2DRD1DRD4 | |
| Phenyltoloxamine SCHEMBL16755246 | 0.82 | DRD1 (0.97) | KDM4ELMNADRD2DRD1DRD4 | |
| Phenyltoloxamine SCHEMBL8510190 | 0.82 | HRH1 (1.00) | KDM4ELMNADRD2DRD1DRD4 | |
| SCHEMBL3862203 | 0.79 | DRD2 (0.74) | KDM4ELMNADRD2DRD1DRD4 | |
| SCHEMBL11754849 | 0.77 | HRH1 (1.00) | KDM4ELMNADRD2DRD1DRD4 | |
| Citric Acid SCHEMBL25265210 | 0.76 | LMNA (0.61) | KDM4ELMNAHRH1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1887 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041777-A1 | PHARMACEUTICAL CAPSULE CONTAINING AT LEAST TWO TABLETS | RB HEALTH US LLC (US) | 2024-02-08 | — | — | US | claimed |
| CN-114796127-A | Iloxamine sustained-release dry suspension and preparation method thereof | 北京斯利安药业有限公司 | 2022-07-29 | — | — | CN | claimed |
| US-20220079937-A1 | PHARMACEUTICAL FORMULATION | RB HEALTH (US) LLC | 2022-03-17 | — | — | US | claimed |
| US-20210046040-A1 | PAIN-RELIEVING TOPICAL COMPOSITIONS | INNOCAN PHARMA LTD. (IL) | 2021-02-18 | — | — | US | claimed |
| EP-3735225-A1 | PAIN-RELIEVING TOPICAL COMPOSITIONS | INNOCAN PHARMA LTD. (IL) | 2020-11-11 | — | — | EP | claimed |
| US-20200261373-A1 | PHARMACEUTICAL CAPSULE CONTAINING AT LEAST TWO TABLETS | RECKITT BENCKISER LLC (US) | 2020-08-20 | — | — | US | claimed |
| EP-3312183-B1 | DEUTERATED MORPHINE DERIVATIVES FOR USE IN ANALGESIA | UNIV SZEGEDI (HU) | 2020-06-17 | — | — | EP | claimed |
| WO-2020012480-A1 | PAIN-RELIEVING TOPICAL COMPOSITIONS | INNOCAN PHARMA LTD. (IL) | 2020-01-16 | — | — | WO | claimed |
| EP-3312183-A1 | DEUTERATED MORPHINE DERIVATIVES | Szegedi Tudományegyetem (HU) | 2018-04-25 | — | — | EP | claimed |
| EP-1476140-B1 | TASTE-MASKED FILM-TYPE OR WAFER-TYPE MEDICINAL PREPARATION | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2018-04-04 | — | — | EP | claimed |
| US-5445829-A | Forming core mixture of immediate release particles containing a drug, inert substrate and binder; coating with talc; spray-coating with dissolution modifying sytem of plasticizer and film-forming agent | KV PHARMACEUTICAL COMPANY (US) | 1995-08-29 | — | — | US | claimed |
| EP-0506207-A2 | Pharmaceutical vehicles for reducing transdermal flux | CHEMEX PHARMACEUTICALS, Inc. (US) | 1992-09-30 | — | — | EP | claimed |
| US-5133974-A | Time release agents formed with binders and coatings over a core | KV PHARMACEUTICAL COMPANY (US) | 1992-07-28 | — | — | US | claimed |
| US-4895727-A | Using water soluble zinc compound | CHEMEX PHARMACEUTICALS, INC. (US) | 1990-01-23 | — | — | US | claimed |
| US-4882151-A | MASKING OF FIBROUS MOUTHFEEL AND UNPLEASANT TASTE | WARNER LAMBERT CO. (US) | 1989-11-21 | — | — | US | claimed |
| EP-0132472-B1 | MEDICATED PRODUCTS CONTAINING A MAGNESIUM TRISILICATE ADSORBENT WITH A MEDICAMENT DRUG ADSORBED THEREON | WARNER-LAMBERT COMPANY (US) | 1989-06-21 | — | — | EP | claimed |
| US-4753800-A | DRUGS ADSORBED ONTO MAGNESIUM ALUMINUM STEARATE | WARNER-LAMBERT COMPANY (US) | 1988-06-28 | — | — | US | claimed |
| EP-0219458-A2 | Medicament adsorbates and their preparation | WARNER-LAMBERT COMPANY (US) | 1987-04-22 | — | — | EP | claimed |
| US-4642231-A | Magnesium trisilicate suitable for preparation of medicament adsorbates of antihistamines | WARNER-LAMBERT COMPANY (US) | 1987-02-10 | — | — | US | claimed |
| EP-0132472-A1 | Medicated products containing a magnesium trisilicate adsorbent with a medicament drug adsorbed thereon | WARNER-LAMBERT COMPANY (US) | 1985-02-13 | — | — | EP | claimed |